DRUG-MONITORING OF ETOPOSIDE (VP16-213) CORRELATION OF PHARMACOKINETIC PARAMETERS TO CLINICAL AND BIOCHEMICAL DATA FROM PATIENTS RECEIVING ETOPOSIDE

被引：0
|
作者：
PFLUGER, KH [1 ]
SCHMIDT, L [1 ]
MERKEL, M [1 ]
JUNGCLAS, H [1 ]
HAVEMANN, K [1 ]
机构：
[1] UNIV MARBURG,FACHBEREICH PHYS CHEM KERNCHEM,D-3550 MARBURG,FED REP GER
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1987年 / 20卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：59 / 66
页数：8
相关论文
共 8 条
  • [1] DRUG-MONITORING OF ETOPOSIDE (VP16-213) .1. A COMBINED METHOD OF LIQUID-CHROMATOGRAPHY AND MASS-SPECTROMETRY
    DANIGEL, H
    PFLUGER, KH
    JUNGCLAS, H
    SCHMIDT, L
    DELLBRUGGE, J
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1985, 15 (02) : 121 - 124
  • [2] PHASE-3 STUDIES WITH ETOPOSIDE (VP16-213) IN LUNG-CANCER PATIENTS
    ISSELL, BF
    ROSENBAUM, PF
    DHAFIR, RA
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 7 (2-3) : 239 - 239
  • [3] TREATMENT OF BRAIN METASTASES OF LUNG-CANCER WITH HIGH-DOSES OF ETOPOSIDE (VP16-213) - COOPERATIVE STUDY FROM THE GROUPE FRANCAIS PNEUMO-CANCEROLOGIE
    KLEISBAUER, JP
    VESCO, D
    OREHEK, J
    BLAIVE, B
    CLARY, C
    POIRIER, R
    SARETTO, S
    CARLES, P
    DONGAY, G
    GUERIN, JC
    MARTINAT, Y
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (02): : 131 - &
  • [4] CIS-PLATINUM (DDP) AND VP16-213 (ETOPOSIDE) COMBINATION CHEMOTHERAPY FOR ADVANCED NONSMALL CELL LUNG-CANCER - A PHASE-II CLINICAL-TRIAL
    MITROU, PS
    GRAUBNER, M
    BERDEL, WE
    MENDE, S
    GROPP, C
    DIEHL, V
    KLIPPSTEIN, TH
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1984, 20 (03): : 347 - 351
  • [5] HIGH-DOSE CYCLOPHOSPHAMIDE, CARMUSTINE (BCNU), AND ETOPOSIDE (VP16-213) WITH OR WITHOUT CISPLATIN (CBV+/-P) AND AUTOLOGOUS TRANSPLANTATION FOR PATIENTS WITH HODGKINS-DISEASE WHO FAIL TO ENTER A COMPLETE REMISSION AFTER COMBINATION CHEMOTHERAPY
    REECE, DE
    BARNETT, MJ
    SHEPHERD, JD
    HOGGE, DE
    KLASA, RJ
    NANTEL, SH
    SUTHERLAND, HJ
    KLINGEMANN, HG
    FAIREY, RN
    VOSS, NJ
    CONNORS, JM
    OREILLY, SE
    SPINELLI, JJ
    PHILLIPS, GL
    [J]. BLOOD, 1995, 86 (02) : 451 - 456
  • [6] Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s disease
    DE Reece
    TJ Nevill
    A Sayegh
    JJ Spinelli
    DA Brockington
    MJ Barnett
    H-G Klingemann
    JM Connors
    SH Nantel
    JD Shepherd
    HJ Sutherland
    NJS Voss
    RN Fairey
    SE O’Reilly
    GL Phillips
    [J]. Bone Marrow Transplantation, 1999, 23 : 1131 - 1138
  • [7] Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin's disease
    Reece, DE
    Nevill, TJ
    Sayegh, A
    Spinelli, JJ
    Brockington, DA
    Barnett, MJ
    Klingemann, HG
    Connors, JM
    Nantel, SH
    Shepherd, JD
    Sutherland, HJ
    Voss, NJS
    Fairey, RN
    O'Reilly, SE
    Phillips, GL
    [J]. BONE MARROW TRANSPLANTATION, 1999, 23 (11) : 1131 - 1138
  • [8] No difference in clinical parameters and drug retention in PsA patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry
    Regierer, Anne Constanze
    Kiefer, David
    Schett, Georg
    Krause, Andreas
    Weiss, Anja
    Sewerin, Philipp
    Strangfeld, Anja
    [J]. RMD OPEN, 2024, 10 (03):
1